Radiopharmaceuticals for Treatment of NETs
Neuroendocrine tumours (NETs) are a group of unusual cancers which develop from cells of the diffuse endocrine system. They are found most commonly in lungs or gastrointestinal system, but they can also originate in other tissues such as pancreas, ovary and testes. A common feature of NETs is that they almost all overexpress somatostatin receptors. For this reason somatostatin receptors have been considered as a target for radiolabelled radiopharmaceuticals. These molecules are constituted by a peptide chain (i.e. a somatostatin-like structure), a partially or totally electron emitter radionuclide and a suitable bifunctional chelator able both to firmly complex the radionuclide as well as to be connected to the peptide chain by means of proper molecular spacers. Nowadays, the most used radiopharmaceuticals for treatments of NETs are [DOTA]0-Tyr3-octreotide (DOTATOC) and [DOTA0]-Tyr3-octreotate (DOTATATE) labelled with yttrium-90 and lutetium-177.
KeywordsYttrium-90 Lutetium-177 Somatostatin analogue PRRT DOTATOC DOTATATE Radiolabelling Quality controls NETs
The author thanks Coruzzi Chiara for the work on the raw material, the proofs for correction and for the bibliographic research.
- 6.Sabet A, Biersack HJ, Ezziddin S. Advances in peptide receptor radionuclide therapy. Semin Nucl Med. 2016;46:40–6.Google Scholar
- 18.Schuchardt C, Kulkarni HR, Prasad V, et al. The bad berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC. In: Baum R, Rösch F, editors. Theranostics, gallium-68, and other radionuclides, Recent results in cancer research, vol. 194. Berlin: Springer; 2013.Google Scholar
- 28.European Directorate for the Quality of Medicines & Healthcare (EDQM). Gallium (68Ga) edotreotide injection. European Pharmacopoeia 7.6. 2013;2482:4847–48.Google Scholar
- 29.European Directorate for the Quality of Medicines & Healthcare (EDQM). Extemporaneous preparation of radiopharmaceutical preparations. Chapter 5.19. In:European pharmacopoeia. 8th ed. Strasbourg: EDQM; 2016.Google Scholar
- 32.International Atomic Energy Agency. Therapeutic radionuclide generators: 90Sr/90Y and 188W/188Re generators, Technical Reports Series No. 470. Vienna: International Atomic Energy Agency; 2009.Google Scholar
- 36.Williams K. Endotoxins. 3rd ed. New York: Informa Healthcare; 2007. p. 27–90.Google Scholar
- 38.Dragotakes SC, Cooper JF, Hubers D. A new system for the rapid detection of endotoxin in PET radiopharmaceuticals. (abstract). 2005. Society of Nuclear Medicine. Toronto.Google Scholar